IL37 and ulcerative colitis: By promoting sustained inflammation and perpetuating the immune response, IL-23 not only exacerbates several diseases, including inflammatory bowel disease, ulcerative colitis, and Crohn’s disease but also represents a promising target for therapeutic intervention aimed at modulating the immune system and alleviating autoimmune inflammatory disease symptoms (18).